CHSY1 Antibody

What applications are CHSY1 antibodies validated for in current research?

CHSY1 antibodies have been validated for multiple research applications including Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Most commercial antibodies are tested against human and mouse samples, with recommended dilutions typically ranging from 1:100-1:300 for IHC applications and 1:500-1:2000 for Western blotting . For immunofluorescence microscopy, researchers typically use dilutions around 1:100 followed by fluorophore-conjugated secondary antibodies such as Alexa Fluor-488 .

What are the recommended controls when using CHSY1 antibodies?

For proper experimental validation, include both positive and negative controls:

• Positive controls: Cell lines known to express CHSY1 such as RKO colorectal cancer cells or AGS/MGC-803 gastric cancer cells

• Negative controls:

  • Primary antibody omission

  • Isotype IgG controls under similar conditions

  • CHSY1-knockdown cells generated through shRNA or siRNA approaches

• Loading control: GAPDH is commonly used as an internal control for normalization

How should I optimize CHSY1 antibody concentration for immunohistochemistry of cancer tissues?

For optimal IHC staining of cancer tissues:

• Start with a titration experiment using recommended dilution ranges (typically 1:100-1:300)

• Use appropriate antigen retrieval: Studies have successfully used citrate buffer (pH 6.0) heated to 100°C for 30 minutes

• Block with normal serum or BSA (3-5%) for 1 hour at room temperature

• Incubate with primary CHSY1 antibody overnight at 4°C

• Incubate with HRP-conjugated secondary antibody (typically 1:3000 dilution) for 2 hours at room temperature

• Develop using DAB substrate and counterstain with hematoxylin

• Score staining based on both intensity (0-3) and percentage (1-4)

For quantification, researchers commonly use a scoring system where intensity is graded as: 0 (no staining), 1 (light yellow), 2 (brown yellow), and 3 (dark brown); while percentage is scored as 1 (1%-24%), 2 (25%-49%), 3 (50%-74%), and 4 (75%-100%) .

What is the recommended protocol for detecting CHSY1 protein levels by Western blot?

For optimal Western blot detection of CHSY1:

• Extract total proteins using RIPA buffer with protease inhibitors

• Quantify protein concentration using BCA protein assay

• Load 20 μg protein per lane on 8-10% SDS-PAGE gels

• Transfer to PVDF membrane

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary CHSY1 antibody (1:500-1:2000 dilution) overnight at 4°C

• Wash with TBST (3 × 10 minutes)

• Incubate with HRP-conjugated secondary antibody (1:3000-1:5000) for 1-2 hours

• Develop using ECL substrate

• Normalize band intensity to loading controls such as GAPDH or β-actin

How can I evaluate CHSY1 knockdown efficiency in functional studies?

To verify effective CHSY1 knockdown:

• Design appropriate shRNA or siRNA targeting CHSY1 (validated sequence example: 5'-ACATTGTCATGCAGGTCAT-3')

• Use lentiviral vectors (such as pGV115-GFP) for stable knockdown, or direct transfection for transient knockdown

• Assess knockdown efficiency at both mRNA and protein levels:

  • mRNA level: Perform RT-qPCR using validated CHSY1 primers:
    Forward: 5'-GCTATCACATTACACCCCAACA-3'
    Reverse: 5'-AACTCCCATTCCAGAATCTCCT-3'

  • Protein level: Western blot using validated CHSY1 antibodies

• Calculate knockdown efficiency as percentage reduction compared to control cells (70% or greater reduction is considered effective)

• Include appropriate controls (non-targeting shRNA/siRNA)

How can I investigate the relationship between CHSY1 expression and TGF-β signaling?

Research has shown that TGF-β induces CHSY1 expression through MAPK signaling and transcription factors including c-Jun and Sp1 . To investigate this:

• Treat cells with TGF-β (typically 10 ng/mL) for various time points (0.5, 1, 4, 8, and 24 hours)

• Assess CHSY1 expression changes by:

  • Western blot - monitor both CHSY1 and phosphorylated signaling proteins (p-Smad2/3, p-ERK1/2, p-p38, p-JNK)

  • RT-qPCR - measure CHSY1 mRNA induction

  • Immunofluorescence - visualize cellular localization changes

• Use specific inhibitors to block signaling pathways:

  • SB431542 for TGF-β receptor

  • U0126 for MEK/ERK

  • SB203580 for p38 MAPK

  • SP600125 for JNK

• Perform CHSY1 promoter reporter assays to evaluate transcriptional regulation:

  • Generate CHSY1 reporter constructs containing promoter region (-1831 to +64)

  • Transfect cells and measure luciferase activity after TGF-β treatment

What might cause inconsistent CHSY1 antibody staining patterns across different cancer types?

Several factors can contribute to variable CHSY1 staining patterns:

• Heterogeneous expression: CHSY1 expression varies across cancer stages and types. For example, some studies show higher expression in stage I colorectal cancer but variable expression in stages II and III

• Tissue-specific post-translational modifications: The protein may undergo different processing in various tissues

• Epitope accessibility: Differences in protein conformation or complex formation may affect antibody binding

• Fixation protocols: Overfixation can mask epitopes while underfixation can cause protein loss

• Antibody specificity: Different antibodies target distinct epitopes, potentially yielding different results

To address these issues:

• Use multiple antibodies targeting different epitopes

• Validate with orthogonal methods (Western blot, IF, and IHC)

• Include positive and negative tissue controls from the specific cancer type being studied

• Optimize fixation and antigen retrieval protocols for each tissue type

How can I troubleshoot non-specific bands in CHSY1 Western blots?

Non-specific bands are common challenges in CHSY1 detection. To troubleshoot:

• Antibody validation:

  • Compare your observed band pattern with published literature

  • Use CHSY1 knockdown/knockout samples as negative controls

  • Consider a peptide competition assay using the immunizing peptide

• Optimization strategies:

  • Increase blocking stringency (5% BSA instead of milk, or add 0.1% Tween-20)

  • Reduce primary antibody concentration

  • Perform more stringent washing steps (increase time/number of washes)

  • Use freshly prepared buffers and reagents

  • Consider using a different CHSY1 antibody that targets a different epitope

• Technical considerations:

  • Ensure proteins are fully denatured (heat samples at 95°C for 5 minutes with reducing agent)

  • Use fresher samples to minimize protein degradation

  • Consider using gradient gels to better resolve proteins of similar sizes

How can CHSY1 antibodies be used to investigate its role in cancer progression?

CHSY1 has been identified as a tumor promoter in multiple cancers including colorectal, gastric, and glioma . To investigate its role:

• Expression profiling:

  • Compare CHSY1 levels between tumor and adjacent normal tissues using IHC

  • Correlate expression with clinicopathological features (tumor stage, grade, patient survival)

• Functional studies:

  • Generate stable CHSY1 knockdown cell lines using validated shRNA sequences

  • Assess effects on:

    • Cell proliferation (CCK-8 or MTT assays)

    • Colony formation

    • Cell migration (wound healing or transwell assays)

    • Apoptosis (Annexin V/PI staining)

    • Cell cycle progression (flow cytometry)

• Mechanistic investigations:

  • Examine downstream signaling pathways (e.g., PDGFRA signaling in glioma)

  • Assess changes in extracellular matrix components and chondroitin sulfate production

  • Investigate interactions with other proteins through co-immunoprecipitation

• In vivo studies:

  • Establish xenograft models using CHSY1-manipulated cells

  • Monitor tumor growth, invasion, and metastasis

  • Perform IHC on harvested tumors to confirm CHSY1 status

What is the methodology for investigating CHSY1's role in nerve regeneration using antibodies?

Recent research has implicated CHSY1 in nerve regeneration processes . To study this:

• Animal models:

  • Establish nerve injury models (e.g., sciatic nerve crush or transection)

  • Apply electrical stimulation (ES) if studying ES-mediated nerve regeneration

• CHSY1 knockdown approaches:

  • Administer siRNA targeting CHSY1 to the injured nerve site

  • Verify knockdown efficiency by qPCR and Western blot at appropriate timepoints (2 weeks and 3 months post-injury)

• Analysis techniques:

  • Analyze CHSY1 expression changes over time (1-3 months) after nerve injury

  • Co-stain with neuronal markers (S100) and extracellular matrix components (versican)

  • Quantify axon regeneration through histological and electrophysiological assessments

  • Correlate CHSY1 levels with functional recovery parameters

• Mechanistic studies:

  • Investigate the relationship between CHSY1 and chondroitin sulfate proteoglycan (CSPG) production

  • Examine interactions with other extracellular matrix components important for nerve regeneration

Can CHSY1 antibodies be used to study glycosaminoglycan synthesis in different research contexts?

Yes, CHSY1 antibodies are valuable tools for studying glycosaminoglycan (GAG) synthesis across multiple research contexts:

• Cartilage biology and osteoarthritis:

  • Quantify CHSY1 expression in normal vs. osteoarthritic cartilage

  • Correlate with chondroitin sulfate production and cartilage integrity

• Developmental biology:

  • Track CHSY1 expression during embryonic development

  • Study its role in morphogenesis and tissue patterning

  • Investigate the connection to Temtamy Preaxial Brachydactyly Syndrome caused by CHSY1 mutations

• Neurological research:

  • Examine CHSY1's involvement in neural extracellular matrix formation

  • Study its role in neurodevelopment and neurological disorders

  • Investigate its function in glial cells vs. neurons

• Quantification approaches:

  • Combine CHSY1 immunoblotting with glycosaminoglycan quantification assays

  • Use specific inhibitors of chondroitin sulfate synthesis to establish causality

  • Apply alcian blue or other GAG-specific stains alongside CHSY1 IHC

For quantifying the relationship between CHSY1 expression and GAG synthesis, researchers can use the dimethylmethylene blue (DMMB) assay to measure sulfated GAG secretion and accumulation following CHSY1 manipulation .

What are the key considerations when using CHSY1 antibodies across different species?

When applying CHSY1 antibodies to different species:

• Sequence homology:

  • Verify the conservation of the antibody's target epitope across species

  • For antibodies raised against human CHSY1, alignment of the immunogen sequence with the target species is critical

• Validation approaches:

  • Test the antibody on known positive control samples from the target species

  • Consider knockdown experiments to confirm specificity in the new species

  • Use multiple antibodies targeting different epitopes for cross-validation

• Species-specific considerations:

  • Mouse/rat tissues may require different fixation and antigen retrieval protocols than human samples

  • Optimize blocking conditions to minimize species-specific background

  • Consider using species-specific secondary antibodies to reduce cross-reactivity

• Expression differences:

  • Be aware that CHSY1 expression patterns and cellular localization may vary between species

  • The molecular weight of CHSY1 might differ slightly between species due to post-translational modifications